Abstract
Over the last years, ligands for angiotensin II subtype 1 receptor (AT1R) have been developed as an alternative to the use of angiotensin-converting enzyme (ACE) inhibitors for controlling high blood pressure. Radiolabeled versions of these ligands have proven vital to the development of more potent and specific drugs for the treatment of hypertension. Imaging studies using radiolabeled AT1R ligands have also elucidated the role these receptors play in angiogenesis as well as in various disease states beyond hypertension.
Keywords: Angiotensin, AT1, carbon-11, hypertension, iodine-125, Losartan, radioligand, tritium, Angiotensin II, (AT1) Receptor, angiotensin-converting enzyme (ACE), renin-angiotensin system (RAS), ACE inhibitors, Physiological regulation, atherosclerosis, renal fibrosis, myocardial remodeling, carcinogenesis, arterial hypertension, Fibrocyte accumulation, extracellular matrix (ECM), protein kinases (MAPKs), renin-angiotensin system, ANG II PEPTIDE ANALOGS, Losartan derivatives, blood-brain barrier (BBB), Candesartan, 18F-labeled AT1 antagonist, Eprosartan, Irbesartan, Telmisartan, Valsartan, Olmesartan, SK-1080, KR31173
Current Topics in Medicinal Chemistry
Title: Radioligands for the Angiotensin II Subtype 1 (AT1) Receptor
Volume: 10 Issue: 16
Author(s): William B. Mathews and Zsolt Szabo
Affiliation:
Keywords: Angiotensin, AT1, carbon-11, hypertension, iodine-125, Losartan, radioligand, tritium, Angiotensin II, (AT1) Receptor, angiotensin-converting enzyme (ACE), renin-angiotensin system (RAS), ACE inhibitors, Physiological regulation, atherosclerosis, renal fibrosis, myocardial remodeling, carcinogenesis, arterial hypertension, Fibrocyte accumulation, extracellular matrix (ECM), protein kinases (MAPKs), renin-angiotensin system, ANG II PEPTIDE ANALOGS, Losartan derivatives, blood-brain barrier (BBB), Candesartan, 18F-labeled AT1 antagonist, Eprosartan, Irbesartan, Telmisartan, Valsartan, Olmesartan, SK-1080, KR31173
Abstract: Over the last years, ligands for angiotensin II subtype 1 receptor (AT1R) have been developed as an alternative to the use of angiotensin-converting enzyme (ACE) inhibitors for controlling high blood pressure. Radiolabeled versions of these ligands have proven vital to the development of more potent and specific drugs for the treatment of hypertension. Imaging studies using radiolabeled AT1R ligands have also elucidated the role these receptors play in angiogenesis as well as in various disease states beyond hypertension.
Export Options
About this article
Cite this article as:
B. Mathews William and Szabo Zsolt, Radioligands for the Angiotensin II Subtype 1 (AT1) Receptor, Current Topics in Medicinal Chemistry 2010; 10 (16) . https://dx.doi.org/10.2174/156802610793176729
DOI https://dx.doi.org/10.2174/156802610793176729 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exploring the Pharmacognostic Features, Anti-oxidant and Lipid Lowering Potential of <i>Fagopyrum esculentum</i> Moench. Seed
Current Traditional Medicine Discovery Approaches for Novel Dyslipidemia Drugs
Current Drug Discovery Technologies Aldose Reductase / Polyol Inhibitors for Diabetic Retinopathy
Current Pharmaceutical Biotechnology Salvianolic Acid B Inhibits Atherogenesis of Vascular Cells through Induction of Nrf2-dependent Heme Oxygenase-1
Current Medicinal Chemistry C-Reactive Protein and Hypertension: Is there A Causal Relationship?
Current Pharmaceutical Design Brain Oxidative Markers in Stress: Possible New Drug Targets Against Neuroinflammation
Current Neuropharmacology Sleep and COPD
Current Respiratory Medicine Reviews Monitoring Kidney Function in Neuroendocrine Tumor Patients Treated with <sup>90</sup>Y-DOTATOC: Associations with Risk Factors
Current Radiopharmaceuticals The Renin Prosequence Enhances Constitutive Secretion of Renin and Optimizes Renin Activity
Current Neurovascular Research Progress Towards Discovery of Antifibrotic Drugs Targeting Synthesis of Type I Collagen
Current Medicinal Chemistry An Efficient and Green Catalytic Method for Friedländer Quinoline Synthesis Using Tungstophosphoric Acid Included in a Polymeric Matrix
Current Catalysis Cardiac Effect of Cholinesterase Inhibitors Used in Alzheimers Disease - from Basic Research to Bedside
Current Alzheimer Research Calcium Metabolism and Oxidative Stress in Bone Fractures: Role of Antioxidants
Current Drug Metabolism Bayes Syndrome and Imaging Techniques
Current Cardiology Reviews A Pharmacological Primer of Biased Agonism
Endocrine, Metabolic & Immune Disorders - Drug Targets Nutrapharmacology of Tocotrienols for Metabolic Syndrome
Current Pharmaceutical Design General Principles for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews Conference Report: 184th American Association for the Advancement of Science Annual Meeting, Austin TX, USA Feb. 15-19, 2018
CNS & Neurological Disorders - Drug Targets Role of WNK Kinases in Blood Pressure Control
Current Hypertension Reviews